Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Particle Sciences, Celanese in Drug-Eluting Device Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Particle Sciences, Celanese in Drug-Eluting Device Pact

PSI to gain preferred access to VitalDose EVA for early-stage projects

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Particle Sciences Inc. (PSI) and Celanese EVA Performance Polymers, a supplier of ethylene vinyl acetate (EVA) into pharmaceutical applications, are collaborating to provide PSI with preferred access to VitalDose™ EVA polymers for early-stage projects.

Andrew Loxley, PSI’s director of New Technologies, remarked, “With combination products — devices that deliver drugs — there are multiple parties involved including the innovator, the API supplier, the development group and the polymer supplier. All parties want to ensure a quality product. Particle Sciences and Celanese EVA Performance Polymers have been collaborating for a number of years and, because of that relationship, are now in a position to expedite the process.”

Jamie Beggs, marketing development manager, Celanese EVA Performance Polymers, commented, “We are committed to becoming the premier EVA excipient producer and have been providing EVA technology for medical applications for years. Our VitalDose brand delivers the reliable performance required for pharma applications combined with in-depth technical expertise and comprehensive regulatory knowledge. This partnership is a testament to the degree to which we have developed confidence in Particle Sciences’ capabilities and their focus on quality. With their capabilities in prototyping, characterization, experience with controlled and highly potent substances and cGMP facilities, they have consistently delivered innovation to our customers.”

Robert Lee, vice president Pharmaceutical Development at PSI, noted, “Combination products have unique development challenges. For each project, it’s important that we start with an open mind as to polymer choice and device architecture. For our EVA needs, we are extremely pleased to be aligned with Celanese EVA Performance Polymers, the group we believe to be most appropriately addressing this market.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters